Why the study?
Does a major GI bleed increase the risk of OAC discontinuation, stroke/SE, major bleeding, and mortality in OAC-treated non-valvular atrial fibrillation patients?
Does a major GI bleed increase the risk of OAC discontinuation, stroke/SE, major bleeding, and mortality in OAC-treated non-valvular atrial fibrillation patients?
Major GI bleeding in OAC-treated NVAF patients is associated with high rates of OAC discontinuation and significantly increased risks of stroke, subsequent bleeding, and mortality.
Major GI bleed on OAC may warrant resumption strategies in NVAF; leaves open net benefit versus harm in prospective trials.
Patients with a major GI bleed on OAC had a high rate of OAC discontinuation and significantly higher risk of stroke/SE, major bleeding, and mortality after hospital discharge than those without. Effective management strategies are needed for patients with risk factors for major GI bleeding.
No takes yet. Share an insight, caveat, or question.
Deitelzweig et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: